Clinical Impact of Factor VIII Prophylaxis in Hemophilia A Patients in Basra, Iraq: A 12‐Month Prospective Study

Background: Hemophilia A is a chronic inherited bleeding disorder associated with recurrent hemorrhage and progressive joint damage. Prophylactic factor replacement therapy is the recommended standard of care, yet evidence from resource‐limited settings remains limited. Methods: This prospective before–after study evaluated 38 hemophilia A patients receiving factor VIII prophylaxis for 12 months at the Basra Center for Hereditary Blood Diseases. Clinical outcomes including bleeding episodes, bleeding severity, therapeutic response, and dose requirements were assessed. Results: Prophylaxis resulted in a 59.8% reduction in total bleeding episodes, complete elimination of severe and post‐surgical bleeding, and a marked improvement in therapeutic response, with a 367% increase in excellent responders. Younger patients demonstrated superior outcomes. Conclusion: Intermediate‐dose prophylaxis significantly improves clinical outcomes in hemophilia A patients in southern Iraq, supporting its broader adoption in resource‐limited settings.